CTOs on the Move

Mitsubishi Tanabe Pharma Development America

www.m-pharma.com

 
Mitsubishi Tanabe Pharma Development America is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.m-pharma.com
  • 25 Independence Blvd Ste 201
    Warren, NJ USA 07059
  • Phone: 908.607.1950

Executives

Name Title Contact Details

Similar Companies

MicroConstants

MicroConstants is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SAMANI

SAMANI is a Whitestone, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

Passage Bio

Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.

Emiliem Inc

Emiliem Inc is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.